Bio-Techne (TECH): financials, SEC filings and peers
Bio-Techne (TECH) is a life sciences tools & services company in the Health Care sector of the S&P 500, headquartered in Minneapolis, Minnesota.
It was founded in 1976 and joined the S&P 500 on August 30, 2021.
Its fiscal year ends in June, and its shares trade on the Nasdaq.
In its SEC filings it is classified as “Biological Products, (No Diagnostic Substances)”.
Bio-Techne at a glance
- Revenue (12 months)
- $1.2B
- Revenue growth
- +0.9%
- Operating margin
- 19.6%
- Net income (12 months)
- $172M
- Free cash flow (12 months)
- $308M
- Cash
- $350M
- Debt
- $400M
- Diluted EPS (12 months)
- $1.09
Twelve months to September 30, 2026, from the 10-Q filed November 6, 2026.
Latest twelve months
Over the twelve months to September 30, 2026, Bio-Techne reported revenue of $1.2 billion, about the same as a year earlier (+0.9%).
Its operating margin was 19.6%, up 10.6 percentage points from a year earlier: for every $100 of sales, about $20 was left as operating profit.
Net income was $172 million (14.0% of revenue), 120.5% higher than a year earlier.
Operating cash flow was $338 million and capital spending $29 million, leaving free cash flow of $308 million (25.1% of revenue).
At the end of the period it held $350 million in cash and $400 million in debt, a net debt position of $50 million.
The diluted share count rose 1.0% in a year, which dilutes existing shareholders.
Five-year trend
- Revenue went from $931 million in fiscal 2021 to $1.2 billion in fiscal 2026, about 5.5% a year.
- Operating margin narrowed from 25.5% to 20.7% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Revenue growth | 18.7% | 2.8% | 2.0% | 5.2% | -0.4% |
| Operating margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Net income | $272M | $285M | $168M | $73M | $182M |
| Free cash flow | $280M | $216M | $236M | $257M | $263M |
| Diluted EPS | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
Fiscal years as reported in Bio-Techne’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed November 6, 2026 — quarterly report
- 8-K filed November 4, 2026 — Other event
- 10-K/A filed October 28, 2026
- 8-K filed September 23, 2026 — Shareholder vote results; Regulation FD disclosure
- 8-K filed September 14, 2026 — Other event
- 10-K filed August 24, 2026 — annual report
- 8-K filed August 12, 2026 — Earnings results; Other event
- 8-K filed June 26, 2026 — Material agreement; Executive or director change
Companies like Bio-Techne
Other S&P 500 companies in Life Sciences Tools & Services:
- AAgilent TechnologiesSanta Clara, California
- CRLCharles River LaboratoriesWilmington, Massachusetts
- DHRDanaher CorporationWashington, D.C.
- ILMNIllumina, Inc.San Diego, California
- IQVIQVIADurham, North Carolina
- MTDMettler ToledoColumbus, Ohio
- TMOThermo Fisher ScientificWaltham, Massachusetts
- WATWaters CorporationMilford, Massachusetts
More from Health Care
Questions about Bio-Techne
Is Bio-Techne's revenue growing?
Yes. Revenue for the twelve months to September 30, 2026 was $1.2 billion, up 0.9% from a year earlier, according to its SEC filings.
Is Bio-Techne profitable?
Yes. It earned $172 million in net income over the twelve months to September 30, 2026, a net margin of 14.0%.
Does Bio-Techne have more cash or more debt?
At September 30, 2026 it had $350 million in cash and $400 million in debt, so more debt than cash.
When did Bio-Techne last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on November 6, 2026.
Which companies are similar to Bio-Techne?
In the S&P 500, Bio-Techne is grouped in Life Sciences Tools & Services within the Health Care sector. Agilent Technologies (A), Charles River Laboratories (CRL), Danaher Corporation (DHR), Illumina, Inc. (ILMN), IQVIA (IQV) are in the same group.
Understand the numbers
Source: Bio-Techne’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.